{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:17:36Z","timestamp":1792513056499,"version":"4.5.0"},"reference-count":91,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T00:00:00Z","timestamp":1475539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    To review the potential drug interactions between low-dose methotrexate (LD-MTX) and nonsteroidal anti-inflammatory drugs (NSAIDs), penicillins, and proton-pump inhibitors (PPIs) given the disparity between interactions reported for high-dose and low-dose MTX to help guide clinicians.\n                    <jats:bold>Data Sources:<\/jats:bold>\n                    A literature search was performed in MEDLINE (1946 to September 2016), EMBASE (1974 to September 2016), and International Pharmaceutical Abstracts (1970 to January 2015) to identify reports describing potential drug interactions between LD-MTX and NSAIDS, penicillins, or PPIs. Reference lists of included articles were reviewed to find additional eligible articles.\n                    <jats:bold>Study Selection and Data Extraction<\/jats:bold>\n                    : All English-language observational, randomized, and pharmacokinetic (PK) studies assessing LD-MTX interactions in humans were analyzed to determine clinical relevance in making recommendations to clinicians. Clinical case reports were assigned a Drug Interaction Probability Scale score.\n                    <jats:bold>Data Synthesis:<\/jats:bold>\n                    A total of 32 articles were included (28 with NSAIDs, 3 with penicillins, and 2 with PPIs [1 including both PPI and NSAID]). Although there are some PK data to describe increased LD-MTX concentrations when NSAIDs are used concomitantly, the clinical relevance remains unclear. Based on the limited data on LD-MTX with penicillins and PPIs, no clinically meaningful interaction was identified.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Given the available evidence, the clinical importance of the interaction between LD-MTX and NSAIDs, penicillins, and PPIs cannot be substantiated. Health care providers should assess the benefit and risk of LD-MTX regardless of concomitant drug use, including factors known to predispose patients to MTX toxicity, and continue to monitor clinical and laboratory parameters per guideline recommendations.\n                  <\/jats:p>","DOI":"10.1177\/1060028016672035","type":"journal-article","created":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T20:08:21Z","timestamp":1475611701000},"page":"163-178","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":45,"title":["Interaction Between Low-Dose Methotrexate and Nonsteroidal Anti-inflammatory Drugs, Penicillins, and Proton Pump Inhibitors"],"prefix":"10.1177","volume":"51","author":[{"given":"Jill J.","family":"Hall","sequence":"first","affiliation":[{"name":"University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Bolina","sequence":"additional","affiliation":[{"name":"Alberta Health Services, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trish","family":"Chatterley","sequence":"additional","affiliation":[{"name":"University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fakhreddin","family":"Jamali","sequence":"additional","affiliation":[{"name":"University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,10,4]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110207."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094474."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090978."},{"key":"e_1_3_3_5_2","unstructured":"Micromedex Solutions. Truven Health Analytics. http:\/\/micromedex.com. Accessed January 15 2016."},{"key":"e_1_3_3_6_2","unstructured":"Lexicomp. Wolters Kluwer. http:\/\/online.lexi.com. Accessed January 15 2016."},{"key":"e_1_3_3_7_2","unstructured":"Methotrexate Drug Monograph. BC Cancer Agency drug manual. http:\/\/www.bccancer.bc.ca\/. Accessed May 25 2016."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ART.39480."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.20"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh512."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(05)70367-7."},{"key":"e_1_3_3_12_2","unstructured":"Metoject Product Monograph. Medexus Inc. 2008. http:\/\/webprod5.hc-sc.gc.ca\/dpd-bdpp\/dispatch-repartition.do?lang=eng. Accessed July 31 2016."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.2.110."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.rhu.0000135555.83088.a2."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh685."},{"key":"e_1_3_3_16_2","unstructured":"ISMP Canada. Severe harm and deaths associated with incidents involving low-dose methotrexate. https:\/\/www.ismp-canada.org\/download\/safetyBulletins\/2015\/ISMPCSB2015-09_Methotrexate.pdf. Accessed August 1 2016."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809202600219"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2008.08.023."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.229104."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-13-RV-119."},{"key":"e_1_3_3_21_2","unstructured":"BDM Pharmacy [software]. Version 9.2.35.0. Saskatoon: BDM IT Solutions Inc;2015."},{"key":"e_1_3_3_22_2","unstructured":"Kroll Pharmacy Software [software]. Version 10. Toronto: Kroll Computer Systems Inc;2015."},{"key":"e_1_3_3_23_2","unstructured":"Pharmaclik Rx [software]. Version 1.0. Markham: McKesson Canada;2015."},{"key":"e_1_3_3_24_2","unstructured":"Sunrise Clinical Manager [software]. Version 15.1. Chicago: Allscripts;2015."},{"key":"e_1_3_3_25_2","unstructured":"eClinician [software]. Version Hyperspace 2015 IU 1. Verona: Epic Systems Corporation;2014."},{"key":"e_1_3_3_26_2","unstructured":"HealthWatch Next Generation [software]. Version 6.0.3. Toronto: Shoppers Drug Mart;2015."},{"key":"e_1_3_3_27_2","first-page":"342","article-title":"Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration","volume":"69","author":"Ellison NM","year":"1985","unstructured":"Ellison NM, Servi RJ. Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration. Cancer Treat Rep. 1985;69:342-343.","journal-title":"Cancer Treat Rep"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)91706-X"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90786-5"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03303.x."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-008-9204-9."},{"key":"e_1_3_3_32_2","first-page":"963","article-title":"Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors","volume":"30","author":"Santucci R","year":"2010","unstructured":"Santucci R, Lev\u00eaque D, Kemmel V, . Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res. 2010;30:963-966.","journal-title":"Anticancer Res"},{"key":"e_1_3_3_33_2","first-page":"3807","article-title":"Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors","volume":"30","author":"Santucci R","year":"2010","unstructured":"Santucci R, Lev\u00eaque D, Lescoute A, Kemmel V, Herbrecht R. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res. 2010;30:3807-3810.","journal-title":"Anticancer Res"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/0897190012442717."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1179\/acb.2006.028"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199630030-00002"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197709222971203."},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197801)41."},{"key":"e_1_3_3_39_2","volume-title":"Stockley\u2019s Drug Interactions","author":"Baxter K","year":"2010","unstructured":"Baxter K, ed. Stockley\u2019s Drug Interactions. 9th ed. London, UK: Pharmaceutical Press; 2010.","edition":"9"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H423."},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_3_3_42_2","first-page":"1356","article-title":"Methotrexate kinetics in rheumatoid arthritis: Is there an interaction with nonsteroidal antiinflammatory drugs?","volume":"15","author":"Ahern M","year":"1988","unstructured":"Ahern M, Booth J, Loxton A, McCarthy P, Meffin P, Kevat S. Methotrexate kinetics in rheumatoid arthritis: Is there an interaction with nonsteroidal antiinflammatory drugs? J Rheumatol. 1988;15:1356-1360.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_43_2","first-page":"1469","article-title":"Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis","volume":"17","author":"Dupuis L","year":"1990","unstructured":"Dupuis L, Koren G, Shore A, Silverman ED, Laxer RM. Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. J Rheumatol. 1990;17:1469-1473.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600790907"},{"key":"e_1_3_3_45_2","first-page":"1008","article-title":"Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis","volume":"17","author":"Skeith KJ","year":"1990","unstructured":"Skeith KJ, Russell AS, Jamali F, Coates J, Friedman H. Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis. J Rheumatol. 1990;17:1008-1010.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.69."},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780341207"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00278469"},{"key":"e_1_3_3_49_2","first-page":"1126","article-title":"Renal effects of low dose methotrexate in rheumatoid arthritis","volume":"20","author":"Seideman P","year":"1993","unstructured":"Seideman P, M\u00fcller-Suur R, Ekman E. Renal effects of low dose methotrexate in rheumatoid arthritis. J Rheumatol. 1993;20:1126-1128.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_50_2","first-page":"1764","article-title":"Pilot investigation of naproxen\/methotrexate interaction in patients with juvenile rheumatoid arthritis","volume":"20","author":"Wallace CA","year":"1993","unstructured":"Wallace CA, Smith AL, Sherry DD. Pilot investigation of naproxen\/methotrexate interaction in patients with juvenile rheumatoid arthritis. J Rheumatol. 1993;20:1764-1768.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb05713.x"},{"key":"e_1_3_3_52_2","first-page":"203","article-title":"Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis","volume":"21","author":"Anaya J-M","year":"1994","unstructured":"Anaya J-M, Fabre D, Bressolle F, . Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol. 1994;21:203-208.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_53_2","first-page":"2072","article-title":"The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg","volume":"22","author":"Kremer JM","year":"1995","unstructured":"Kremer JM, Hamilton RA. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol. 1995;22:2072-2077.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/34.5.421"},{"key":"e_1_3_3_55_2","first-page":"984","article-title":"Lack of interaction between bromfenac and methotrexate in patients with rheumatoid arthritis","volume":"23","author":"Gumbhir-Shah K","year":"1996","unstructured":"Gumbhir-Shah K, Cevallos WH, DeCleene SA, Korth-Bradley JM. Lack of interaction between bromfenac and methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1996;23:984-989.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_56_2","first-page":"845","article-title":"Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis","volume":"24","author":"Hubner G","year":"1997","unstructured":"Hubner G, Sander O, Degner FL, Turck D, Rau R. Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1997;24:845-851.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-081X(199804)19:3<163::AID-BDD82>3.0.CO;2-L."},{"key":"e_1_3_3_58_2","first-page":"2539","article-title":"Celexoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis","volume":"26","author":"Karim A","year":"1999","unstructured":"Karim A, Tolberta DS, Hunt TL, Hubbard RC, Harper K, Geis GS. Celexoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol. 1999;26:2539-2543.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122012616"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E044."},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740510017977."},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009338939."},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)91707-1"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780331102"},{"key":"e_1_3_3_65_2","first-page":"1274","article-title":"Low dose MTX and NSAID induced \u201cmild\u201d renal insufficiency and severe neutropenia","volume":"18","author":"Kraus A","year":"1991","unstructured":"Kraus A, Alarcon-Segovia D. Low dose MTX and NSAID induced \u201cmild\u201d renal insufficiency and severe neutropenia. J Rheumatol. 1991;18:1274.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_66_2","first-page":"1297","article-title":"Aspirin is not associated with more toxicity than other nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis treated with methotrexate","volume":"20","author":"Rooney TW","year":"1993","unstructured":"Rooney TW, Furst DE, Koehnke R, Burmeister L. Aspirin is not associated with more toxicity than other nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis treated with methotrexate. J Rheumatol. 1993;20:1297-1302.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02229705."},{"key":"e_1_3_3_68_2","first-page":"928","article-title":"Methotrexate\/naproxen-associated severe hepatitis in a child with juvenile idiopathic arthritis","volume":"25","author":"Ting TV","year":"2007","unstructured":"Ting TV, Hashkes PJ. Methotrexate\/naproxen-associated severe hepatitis in a child with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2007;25:928-929.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1996.tb00186.x"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1991.tb93847.x"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005280100."},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7352.1497"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090153."},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120345."},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000404."},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2293."},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000046."},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050840."},{"key":"e_1_3_3_79_2","first-page":"1913","article-title":"Effect of penicillin on the renal tubular secretion of methotrexate in the monkey","volume":"44","author":"Williams WM","year":"1984","unstructured":"Williams WM, Chen TS, Huang KC. Effect of penicillin on the renal tubular secretion of methotrexate in the monkey. Cancer Res. 1984;44:1913-1917.","journal-title":"Cancer Res"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1177\/104345429000700105"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000951.pub2."},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199310000-00004."},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.FTD.0000016421.55770.47."},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl196."},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.08.027."},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19094."},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncolo-gist.2008-0132."},{"key":"e_1_3_3_88_2","unstructured":"Horn JR Hansten PD. Methotrexate and proton pump inhibitors. Pharmacy Times. http:\/\/www.pharmacytimes.com\/publications\/issue\/2012\/april2012\/methotrexate-and-proton-pump-inhibitors. Accessed May 6 2016."},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1211\/jpp.59.9.0011."},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155213482602."},{"key":"e_1_3_3_91_2","unstructured":"Health Canada. New safety information: interaction of proton pump inhibitors (PPIs) with methotrexate. http:\/\/www.healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2012\/15076a-eng.php. Accessed May 6 2016."},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831010-00003"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028016672035","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028016672035","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028016672035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:36Z","timestamp":1777374996000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028016672035"}},"subtitle":["A Narrative Review of the Literature"],"short-title":[],"issued":{"date-parts":[[2016,10,4]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1177\/1060028016672035"],"URL":"https:\/\/doi.org\/10.1177\/1060028016672035","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,4]]}}}